Healthcare / BiotechnologyNasdaqCM
$6.69
-0.53 (-7.34%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 25%
FCF escenarios
weak_data · normalized FCF $-6.6M · quality 52.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
19/100
F
Piotroski
2/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$59M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-57.7%
↓Gross Margin
N/A
•Debt/Equity
N/A
•TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2012–2025 · 13 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
—
FCF / Net income
1.02x
Latest source
Provider fallback
Margin decomposition
Último año: revenue — · net income $-7.2M · FCF $-7.3M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||||||
| Revenue | — | — | — | — | — | $0.00 | $328801.00 | — | $211849.00 | $228287.00 | $1.3M | $758689.00 | — | $545469.00 | $286054.00 |
| Net Income | $-7.2M | $-7.2M | $-6.2M | $-8.4M | $-17.5M | $-13.3M | $-6.4M | — | $-5.0M | $-5.0M | $-5.0M | $-2.8M | — | $-14.5M | $-5.5M |
| EBITDA | $-7.0M | $-7.0M | $-6.1M | $-8.5M | $-17.5M | $-23.6M | $-6.3M | — | $-4.9M | $-5.0M | $-4.8M | $-4.2M | — | — | — |
| EPS | -1.27 | -1.27 | -1.93 | -2.93 | -7.35 | — | — | — | — | — | -167.58 | -105.84 | — | -826.14 | — |
| Operating Margin | — | — | — | — | — | — | -1946.7% | — | -2397.1% | -2288.6% | -386.0% | -571.9% | — | — | — |
| Net Margin | — | — | — | — | — | — | -1935.3% | — | -2378.6% | -2203.7% | -395.2% | -374.7% | — | -2657.5% | -1932.9% |
| Balance Sheet | |||||||||||||||
| Debt/Equity | — | — | 0.01 | 0.01 | 0.00 | — | — | — | — | — | — | — | — | — | — |
| Current Ratio | 16.82 | 16.82 | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Cash Flow | |||||||||||||||
| Free Cash Flow | $-7.3M | $-7.3M | $-4.9M | $-6.6M | $-12.3M | $-13.7M | $-5.0M | — | $-5.0M | $-5.0M | $-4.9M | $-4.7M | — | — | — |
| Returns | |||||||||||||||
| ROE | -57.7% | -57.7% | -311.4% | -118.8% | -186.9% | -102.2% | -96.0% | — | -44.6% | -68.0% | -40.8% | -35.5% | — | 660.1% | -612.9% |
| Valuation | |||||||||||||||
| P/B | 3.05 | 3.05 | 6.88 | 1.73 | 1.86 | — | — | — | — | — | — | — | — | — | — |
| Growth & Yield | |||||||||||||||
| Revenue Growth | — | — | — | — | — | -100.0% | — | — | -7.2% | -82.0% | 67.6% | — | — | 90.7% | — |
| EPS Growth | 34.2% | 34.2% | 34.1% | 60.1% | — | — | — | — | — | — | -58.3% | — | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+241.3%
Start / end P/E
n/dx → n/dx
EPS bridge
-1.93 → -1.27
Residual
+241.3%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.